SciBase Holding AB, a leading developer of augmented intelligence-based solutions for skin disorders, announced on June 9, 2025, the launch of its Nevisense Self-Pay Program in the United States. This new initiative is designed to significantly improve patient access to the Nevisense test for early melanoma detection, particularly for individuals whose access might be limited by traditional insurance coverage.

The program is being rolled out at various dermatology practices across the US that have enrolled in the self-pay solution. SciBase plans to further expand the program's reach to meet the growing needs of both clinicians and patients. The initiative directly addresses the increasing demand for the Nevisense test from patients seeking proactive skin health management and dermatologists aiming to provide advanced diagnostic tools.

The impetus for the Self-Pay Program stems from evolving standards of care in dermatology and a heightened clinical emphasis on the critical importance of early melanoma detection. Dermatologists have expressed strong interest in making Nevisense readily available to all patients, regardless of their insurance payer status. This program empowers clinicians to integrate Nevisense into their diagnostic workflow more promptly, ensuring that patients at risk for melanoma are not subjected to delays due to insurance constraints.

Pia Renaudin, CEO of SciBase, commented on the launch: "We continue to work diligently to expand payer coverage and reimbursement, but we also recognize the urgent need for early detection. The Self-Pay Program is a critical step in making Nevisense more widely available to clinicians and patients who value early, accurate melanoma detection at the point of care."

With melanoma rates continuing to rise globally, the significance of early diagnosis has never been more pronounced. Nevisense offers a crucial point-of-care solution that utilizes a combination of AI and advanced Electrical Impedance Spectroscopy (EIS) technology. This enhances clinical decision-making and supports earlier detection of melanoma, which can ultimately lead to improved patient outcomes and a reduction in the long-term burden on healthcare systems.

Through the introduction of the Self-Pay Program, SciBase reinforces its dedication to innovation, broader patient access, and the promotion of sustainable healthcare practices. This initiative not only enables more patients to benefit from the advanced diagnostic capabilities of Nevisense but also assists clinicians in delivering exceptional care through timely and accurate melanoma detection.

SciBase is a global medical technology company specializing in early detection and prevention within the field of dermatology. The company develops, manufactures, and commercializes Nevisense, its unique point-of-care platform. Built on over two decades of research at the Karolinska Institute in Stockholm, Sweden, SciBase is recognized as a leader in dermatological advancements. SciBase has been listed on the Nasdaq First North Growth Market exchange since June 2, 2015.